FDA Grants Priority Review Voucher for Rare Pediatric Drug
Published Date: 5/11/2026
Notice
Summary
The FDA just gave Denali Therapeutics a special priority review voucher for their rare pediatric disease drug AVLAYAH, approved in March 2026. This voucher speeds up the review of future medicines, helping kids with rare diseases get treatments faster. It’s a big win for patients, the company, and anyone watching rare disease drug development!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
New FDA Approval for Hunter Syndrome Pediatrics
AVLAYAH (tividenofusp alfa-eknm) was approved March 24, 2026 for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II). The approval applies when treatment is started in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.
Priority Review Voucher Awarded to Sponsor
The FDA issued a priority review voucher to Denali Therapeutics Inc. for AVLAYAH (tividenofusp alfa-eknm); AVLAYAH was approved March 24, 2026. The voucher was awarded under section 529 of the Federal Food, Drug, and Cosmetic Act.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
Previous / Next Documents
Previous: 2026-09241 — Notice of Receipt of Amended Complaint; Solicitation of Comments Relating to the Public Interest
The U.S. International Trade Commission got an updated complaint about certain pickleball paddles, involving several companies across the U.S. and one from Spain. They want the public to share their thoughts on how this might affect everyone, especially before any decisions are made. This could impact imports, sales, and competition, so keep an eye out for deadlines to speak up!
Next: 2026-09243 — Certain Photodynamic Therapy Systems, Components Thereof, and Pharmaceutical Products Used in Combination With the Same; Notice of the Commission's Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order and Cease and Desist Orders; Termination of the Investigation
The U.S. International Trade Commission found that some photodynamic therapy devices and related products imported by certain companies broke patent rules. To fix this, they’re blocking these products from entering the U.S. without permission and ordering the companies to stop selling them. This means affected businesses must act fast or face legal and financial consequences.